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The liver isoform of GP is the rate limiting enzyme of glycogen metabolism and is, therefore, directly responsible for regulating 40 blood sugar levels. Evidence are accumulating that in the non-insulin dependent (type 2) form of diabetes mellitus, 2 comprising more than 90% of all diagnosed cases, 3, 4 elevated hepatic glucose output is the most important cause of hyperglycemia. [5] [6] [7] [8] Thus, GP is a validated target for the treatment of type 2 diabetes and its inhibition appears of great interest in both academia and industry. [9] [10] [11] GP has six known binding sites for which several inhibitors have been identified. 12, 13 Among these, glucose-based compounds represent a large family with the capability of binding at the catalytic site of the enzyme in most cases with very high selectivity. [14] [15] [16] N-Acetyl-b-D-glucopyranosylamine 17 (1, Chart 1) was among the first efficient glucose analogue inhibitors of rabbit muscle GPb (RMGPb Chart 1). This feature was then considered as a main contribution to the strong binding of glucose analogues at the catalytic site of GP, and became almost a dogma for further inhibitor design. In the cases of the spiro-hydantoins, the rigid structure of the planar (thio)hydantoin rings, and that of the bicyclic ring system as a whole was also accounted for the tight binding. 22, 23 In recent years, we have introduced several new classes of glucose-based compounds as inhibitors of GP displaying inhibition site. This is further corroborated by the comparison of inhibition by 9 and 10 ($14-fold increase) showing that the orientation of the aromatic part of the molecule is extremely important in order to properly fit into the b-channel as it was also demonstrated by Xray crystallography. 28 Based on these findings, we envisaged that a novel design principle for efficient glucose-based inhibitors of GP can be set up which unifies the properties of the best inhibitors (see generalized formula B in Chart 1): (i) such molecules should have a rigid spirobicyclic scaffold in which a (preferably five-membered het-100 ero)cycle is attached to the anomeric carbon of b-D-glucopyranose, (ii) this cycle, although it may, should not necessarily be a H-bond donor towards His 377 and (iii) a suitably oriented, large aromatic appendage must be present on this cycle to fit into the b-channel.
In this letter we present some glucopyranosylidene-spiro-oxathiazoles as the first compounds which meet the above design principle and one of them is the most efficient glucose analogue inhibitor of GP known to date.
The synthesis of glycopyranosylidene-spiro-oxathiazoles in a minimum number of steps was previously reported. 33, 34 Besides 110 the known 14a, 33 we synthesized substituted phenyl derivatives 
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strated and the main product was isolated by column chromatography. The GP inhibitor candidates were evaluated for their inhibition against RMGPb enzyme as previously described 40 and the obtained inhibitor constants (K i ) are shown in Scheme 1. The phenyl derivative 14a proved $5 times weaker inhibitor than the corresponding acyl urea 8. Substitution of the phenyl ring in the 4-position by a fluorine (14b) brought about no change probably due to the similar size of the H and F atoms. Introduction of a methoxy group into the same position (14c) made a $3 times better inhibitor than 14a suggesting that a bulky substituent on the phenyl ring can be beneficial. Finally, the 2-naphthyl derivative (14d) inhibited the enzyme $2 times stronger than 10. These preliminary results demonstrate that the combination of a rigid spiro-bicyclic structure with the introduction of a large hydrophobic aromatic moiety in a proper orientation for an optimal interaction with the enzyme significantly improves the biological activity of the molecules. The 2-naphthyl substituted derivative 14d is the most potent glucose-based inhibitor of GP to date with an inhibition in the nanomolar range. Based on these preliminary results, we are now synthesizing a more populated family of glucopyranosylidenespiro-oxathiazoles for their biological evaluation as GP inhibitors. These molecules are expected to bind at the catalytic site of GP and further enzymatic and crystallographic investigations will be reported elsewhere.
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